Encompass More Asset Management Halozyme Therapeutics, Inc. Transaction History
Encompass More Asset Management
- $335 Billion
- Q1 2025
A detailed history of Encompass More Asset Management transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, Encompass More Asset Management holds 3,677 shares of HALO stock, worth $214,148. This represents 0.07% of its overall portfolio holdings.
Number of Shares
3,677Holding current value
$214,148% of portfolio
0.07%Shares
1 transactions
Others Institutions Holding HALO
# of Institutions
586Shares Held
123MCall Options Held
320KPut Options Held
113K-
Black Rock Inc. New York, NY17.6MShares$1.03 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA12.8MShares$747 Million0.02% of portfolio
-
State Street Corp Boston, MA6.05MShares$353 Million0.02% of portfolio
-
Invesco Ltd. Atlanta, GA3.89MShares$227 Million0.05% of portfolio
-
Snyder Capital Management L P San Francisco, CA3.67MShares$214 Million5.31% of portfolio
About HALOZYME THERAPEUTICS, INC.
- Ticker HALO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 139,288,992
- Market Cap $8.11B
- Description
- Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...